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Bitter orange (Citrus aurantium) extract and its primary protoalkaloid p-synephrine are used widely in weight loss/weight
management and sports performance products. Because of structural similarities, the pharmacological eﬀects of p-synephrine are
widely assumed to be similar to those of ephedrine, m-synephrine (phenylephrine), and endogenous amine neurotransmitters
as norepinephrine and epinephrine. However, small structural changes result in the receptor binding characteristics of these
amines that are markedly diﬀerent, providing a plausible explanation for the paucity of adverse eﬀects associated with the wide-
spread consumption of p-synephrine in the form of dietary supplements as well as in various Citrus foods and juices. This
papersummarizestheadrenoreceptorbindingcharacteristicsofp-synephrinerelativetom-synephrine,norepinephrine,andother
amines as related to the observed pharmacological eﬀects.
1.Introduction
p-synephrine (Figure 1) is the primary protoalkaloid in
Citrus aurantium (bitter orange) and other Citrus species [1–
14]. Bitter orange extract and p-synephrine are widely used
in weight management and sports performance products.
In addition to its consumption in dietary supplements, p-
synephrine is daily consumed in various foods and juices
derived from Citrus species as Seville oranges, mandarin
oranges, clementines, Marrs sweet oranges, Nova tangerines,
grapefruits and other orange-related species containing p-
synephrine [12–15]. In spite of the wide-spread consump-
tion and the lack of directly attributable adverse eﬀects to p-
synephrine and bitter orange extract [16–18], the safety of
p-synephrine is frequently questioned. Various articles refer
to the potential cardiovascular hazards that may occur as the
result of using dietary supplements containing p-synephrine
and bitter orange extract [19–24], with reference being
made to clinical case reports that involve multiherbal and
polyalkaloidal and poly-protoalkaloidal products [16, 17].
Current confusion regarding the safety of bitter orange
extract and p-synephrine is clouded by multiple issues,
including the use of complex mixtures of ingredients in
products that include bitter orange extract, the existence
of some structural similarities with ephedrine (Figure 2),
the misunderstandings regarding the isomeric forms of
synephrine and their diﬀering pharmacological properties
[18], and the release of misleading information by gov-
ernmental agencies [25]. The projected warnings regarding
cardiovascular risks are extrapolated from studies involv-
ing m-synephrine (Figure 3) and ephedrine which are not
constituents of bitter orange, extract. Furthermore, m-
synephrine does not occur naturally in plants, including
Citrusspecies[1–15].PellatiandBenvenuti[26]summarized
19 chromatographic and electrophoretic analytical methods
for synephrine protoalkaloids in bitter orange and in no case
was m-synephrine detected.
p-synephrine (see Figure 1) is a phenylethanolamine
derivative with the hydroxy group in the paraposition on
the benzene ring of the molecule [3, 6, 8, 10], while m-
synephrine(Figure 3),whichisalsoknownasphenylephrine,
has a hydroxylgroup in the metaposition on the benzene ring
[10]. As shall be discussed, the location of the hydroxygroup
on the ring greatly alters the receptor binding characteristics2 Oxidative Medicine and Cellular Longevity
and as a consequence greatly alters the pharmacological
properties.
p-synephrine is structurally related to ephedrine [3, 6, 8]
(Figure 2). However, ephedrine is a phenylpropanolamine
(Figure 4) derivative and does not contain a para-substituted
hydroxy group. The addition of the parahydroxygroup
on the p-synephrine molecule, as well as the lack of
the methyl group on the side chain change the stere-
ochemistry and as a consequence the receptor binding
characteristics and the pharmacokinetic properties, includ-
ing the ability of p-synephrine to cross the blood-brain
barrier. The lipid solubility of p-synephrine as compared
to ephedrine is signiﬁcantly decreased, resulting in little
transport of p-synephrine into the CNS as compared
to ephedrine [27]. As will be discussed, as a result of
these structural diﬀerences, p-synephrine exhibits little
or no CNS and cardiovascular stimulation as compared
to ephedrine (Figure 2), norepinephrine (noradrenaline;
Figure 5), epinephrine (adrenaline; Figure 6), m-synephrine
(Figure 3), and amphetamine (Figure 7).
Most review articles regarding p-synephrine and bit-
ter orange extract assume that because of the struc-
tural similarities, p-synephrine, m-synephrine, ephedrine,
norepinephrine (Figure 5), epinephrine (Figure 6), and
amphetamine (Figure 7) all exert similar properties and fail
to consider or discuss the receptor binding studies that have
been conducted [19–24]. This paper summarizes the studies
that have been conducted to date on the adrenoreceptor
binding properties of p-synephrine relative to m-synephrine
(phenylephrine), norepinephrine, and other amines. The
results provide a receptor-based foundation for explaining
and interpreting the pharmacological eﬀects as well as the
paucity of toxicological eﬀects of p-synephrine observed in
human clinical as well as animal studies.
2. Receptor Binding Studies
In general, vasoconstriction is produced when ligands acting
as agonists bind to α-adrenoreceptors, cardiovascular con-
tractility and increased heart rate occur in response to β-
1 adrenoreceptor binding, while bronchodilation occurs in
response to β-2 adrenoreceptor binding [24]. As previously
noted, it is widely assumed that p-synephrine exhibits mech-
anistic properties similar to those observed for ephedrine,
norepinephrine, and m-synephrine due to some structural
similarities [19–24]. However, this assumption is not borne
out based on the receptor binding studies discussed below
which indicate that p-synephrine exhibits little binding
aﬃnity for α-a sw e l la sβ-1 and β-2 adrenoreceptors.
Based on receptor binding studies using human and
animal cells, m-synephrine exerts its eﬀects on α-,β-1 and
β-2adrenergicreceptors[28–32]resultinginincreasedblood
pressure and heart rate eﬀects. Jordan et al. [28]c o m p a r e d
the receptor binding activities of m-a n dp-synephrine and
m-a n dp-octopamine (N-demethyl p-synephrine; Figure 8)
with norepinephrine in guinea pig atria and trachea [28].
p-synephrine represents over 90% of the protoalkaloids in
bitter orange extract [12, 13], while p-octopamine is a minor




















metaisomers do not occur in bitter orange extract [1–15]. In
this study [28], m-synephrine was found to be 100-fold and
p-synephrine 40,000-fold less potent than norepinephrine
while the two octopamine isomers were about 6000-fold less
potent than norepinephrine with respect to binding to β-
1a n dβ-2 adrenoreceptors. The results indicate that small
but crucial structural diﬀerences translate into markedly
diﬀerent receptor binding characteristics.
The binding aﬃnities of p-synephrine, m-synephrine,
β-phenethylamine, and nor-ephedrine were compared
by Ma et al. [29] on selected human α-adrenoreceptor
subtypes. With respect to human α-1a adrenoreceptors,
p-synephrine gave a maximal response at 100μM that was
equal to 55% of the m-synephrine maximum. However, this












Figure 6: Epinephrine (Adrenaline).
greater than the blood levels (2ng/mL) obtained when a
dose of 46.9mg p-synephrine is consumed orally and has
little or no eﬀect on heart rate or blood pressure [33]. In
addition, the presence of the parahydroxyl on p-synephrine
reduced the receptor binding with respect to human α-2a
and α-2c adrenoreceptors [29]. The authors concluded that
p-synephrine may act as an antagonist rather than an agonist
of presynaptic α-2a and α-2c adrenoreceptors present in
nerve terminals [29]. Therefore, p-synephrine would not be
expected to produce signiﬁcant vasoconstriction as a result
of binding to these receptors.
Brown et al. [30] compared the binding activities of the
meta-a n dparaisomers of synephrine and octopamine to
rat aorta α-1 and rabbit saphenous vein α-2 adrenore-
ceptors. The binding of m-synephrine to α-1 and α-2
adrenoreceptors was 6-fold and 150-fold less, respectively,
than norepinephrine. Furthermore, p-synephrine and p-
octopamine were 1000-fold less active than norepinephrine
in binding to these two receptors, again demonstrating that
m-synephrine much more actively binds to these receptors
than p-synephrine. Based on these receptor binding studies,
p-synephrine would be expected to exert little vasoconstric-
tion and, therefore, little or no eﬀect on blood pressure as
compared to m-synephrine or norepinephrine.
Hwa and Perez [31] examined the structural features
necessary for binding of ligands to the α-1a adrenoreceptor
and its subsequent activation. They concluded that it is
the metahydroxy of m-synephrine that hydrogen bonds to
a speciﬁc serine moiety at the receptor site as opposed
to the parahydroxy of p-synephrine. Thus, based on this
study, m-synephrine (phenylephrine) binds and activates the
receptor resulting in vasoconstriction and an increase in
blood pressure, while p-synephrine does not.
Hibino et al. [32] examined the ability of p-synephrine to
constrict isolated rat aorta at concentrations of 1 × 10
−7 to
3 × 10
−5 M. Using selected receptor antagonists, the authors








1 adrenoreceptors and serotonergic (5-HT1D and 5-HT2A)
receptors. Again, the concentrations of p-synephrine used
to produce aortic constriction were signiﬁcantly higher than
the peak blood levels (2ng/mL) observed when 46.9mg p-
synephrine was given orally to human subjects and exerted
little or no eﬀect on heart rate or blood pressures [33]. For
example, a concentration of 1 × 10−6 M is approximately
80-fold higher than the blood levels obtained in the above
study with orally administered p-synephrine [3]a tad o s e
of p-synephrine that is at the high end of doses commonly
used in oral preparations for weight management and
sports performance. These results suggest that p-synephrine
may produce vasoconstriction but only at concentrations
many times above the blood levels achieved under normal
conditions of oral usage.
Rossato et al. [34] examined the uptake of p-synephrine
and m-synephrine by rat cardiomyocytes at 1mM concen-
trations and the eﬀects of these two isomers on intracellular
glutathione content. Both isomers were taken up by the cells
with only the m-synephrine resulting in a depletion of both
total and reduced glutathione. The eﬀect was independent
of α-1 adrenoreceptor stimulation since prazosin was not
able to alter m-synephrine-induced glutathione depletion.
The concentration of the two isomers that was used was
over 80,000-fold higher than the 2ng/mL peak blood levels
observed following oral ingestion of 46.9mg p-synephrine
[33]. Thus, the clinical relevance of the results is ques-
tionable. However, the study does demonstrate that the
cardiomyocytes diﬀerentiate between the two isomers, and
only the metaisomer produced a potentially toxic eﬀect.
Activation of β-3 adrenoreceptors has been shown to
reduce food intake and weight gain in rats as well as
enhance lipolysis in adipose tissue, while improving insulin
resistance, glycemic control, and lipid proﬁles [35–38]. β-
3 adrenoreceptors endogenously exist in white and brown
adipose tissues and muscle, and activation increases lipolysis
and lipid metabolism [35, 37, 38]. Increased expression of4 Oxidative Medicine and Cellular Longevity
β-3 adrenoreceptor mRNA was shown to be associated with
lower fasting plasma glucose, insulin, leptin, adiponectin,
and lipids in obese Zucker rats [36]. Furthermore, stud-
ies indicate that β-3 adrenoreceptor-mediated lipolysis in
adipocytes is mediated via the adenyl cyclase/cAMP/protein
kinase A signaling cascade with downstream production
of nitric oxide (NO). Thus, p-synephrine may act as a β-
3 adrenoreceptor agonist, resulting in increased metabolic
rate and lipolysis [27, 35, 39–42] as well as exhibiting
hypoglycemic and insulin stimulatory properties [43, 44]. In
contrast, Shannon et al. [45] have shown that epinephrine
(adrenaline) lacks binding to human β-3 adrenoreceptors
while its thermogenic eﬀects result from direct β-1/2
adrenoreceptor binding.
Carpene et al. [41] assessed the lipolytic action of various
potential β-3 adrenoreceptor agonists in white fat cells from
humans, rats, hamsters, dogs, and guinea pigs. p-synephrine
was partially active in stimulating lipolysis in all species
while dopamine, tyramine, and β-phenylethylamine were
ineﬀective. p-octopaminewasshowntobethemostselective
for β-3 adrenoreceptors. In a Chinese hamster ovary cell
line expressing β-3 adrenoreceptors, p-octopamine exhibited
binding with only twofold less aﬃnity than norepinephrine.
Tsujita and Takaku [42] have shown that a segment
w a l le x t r a c tr i c hi np-synephrine from mandarin oranges
inducedlipolysisinratfatcellsinaconcentration-dependent
manner. A juice sac extract from this same source failed to
induce lipolysis. The nonselective β-antagonist propranolol
completely inhibited lipolysis, indicating the involvement
of a β-adrenoreceptor. The α-antagonist phenoxybenzamine
had no eﬀect on lipolysis indicating a lack of involvement of
α-adrenoreceptors. These studies provide additional mech-
anistic insight into the thermogenic and potential weight
management eﬀects of p-synephrine.
Parmar and Kar [43, 44] have examined the eﬀects of a
Citrus sinensis peel extract on various metabolic parameters
in rats and mice. At a dose of 25mg/kg, the extract exhibited
hypoglycemic, insulin stimulatory, antiperoxidative, antithy-
roidal, and cardioprotective properties and decreased the
concentrations of cholesterol and triglycerides in serum after
daily dosing for 10 days. Decreases in lipid peroxidation
were observed in heart, liver, and kidneys of rats [43]. These
responses are consistent with β-3 adrenoreceptor activation
[35–38]. However, exhibited hypoglycemic, insulin stimu-
latory, antiperoxidative, antithyroidal, and cardioprotective
properties and decreased the concentrations of cholesterol
andtriglycerides in serum,the authorsdid not determine the
content of p-synephrine or other constituents in the extracts,
nor did they assess β-3 adrenoreceptor binding.
The above studies by Parmar and Kar [43, 44]a r ec o n -
sistent with the results of Arbo et al. [46] who treated mice
daily with bitter orange extract (7.5% p-synephrine) at doses
of 400, 2,000, or 4,000mg/kg (corresponding to 30, 150, and
300mg p-synephrine/kg) or 30 or 300mg p-synephrine/kg.
A reduction in body weight gain was observed at all doses,
while no eﬀects were observed on organ weights, biochemi-
cal parameters, blood pressure, or heart rate in the treated
mice relative to controls. Both doses of p-synephrine
and the high dose of the bitter orange extract increased
hepatic-reduced glutathione, while bitter orange extract
decreased lipid peroxidation, and p-synephrine increased
the antioxidant enzyme catalase by 6-fold. These antioxidant
and tissue-protective properties of bitter orange extract and
p-synephrine are consistent with the widely demonstrated
beneﬁcial eﬀects of plant polyphenols [47, 48]. However, it
should be noted that a dose of p-synephrine at 300mg/kg
is up to 600× doses commonly used in humans. Hansen
et al. [49] have reported that a daily dose of p-synephrine of
100mg/kg given to pregnant rats does not produce maternal
or developmental toxicity.
Mercader et al. [50] compared the lipolytic activity
of p-synephrine, p-octopamine, tyramine, and N-methyltyr-
amine as well as the synthetic product isopropyl-norsy-
nephrine in rat and human adipocytes against the proto-
typicalβ-adrenoreceptoragonistisoprenaline.p-octopamine
(Figure 8) was slightly more active at stimulating lipoly-
tic activity than p-synephrine, while tyramine and N-
methyltyramine exhibited modest inhibitory activity. p-
synephrine did not amplify the β-adrenergic component of
epinephrine (adrenaline). Furthermore, p-synephrine was
unable to block α-2 adrenoreceptors and did not provoke
noticeable stimulation of glucose transport suggesting an
impairment of insulin-activated glucose transport. These
results strongly suggest but do not prove the involvement
of β-3 adrenoreceptors. It can be concluded that with
respect to bitter orange extracts the higher the amount of p-
synephrine and the lower the amounts of tyramine and N-
methyltyramine the more the lipolytic activity. As previously
noted,p-octopamineiseitherabsentorpresentinveryminor
amounts in bitter orange extracts [1–15].
In recent years, β-3 adrenoreceptors have been identiﬁed
in cardiovascular tissues, and this observation has challenged
the classical paradigm of sympathetic regulation by β-1
and β-2 adrenoreceptors [51, 52]. Evidence suggests that
activation of cardiovascular β-3 adrenoreceptors produces
a negative inotropic eﬀect that antagonizes β-1 and β-
2 adrenoreceptor activity, resulting in the modulation of
sympathetic overstimulation [51]. The mechanism of action
of this β-3 adrenoreceptor eﬀect is believed to occur through
regulation of nitric oxide [51]. Thus, one can postulate
that p-synephrine stimulation of β-3 adrenoreceptors in the
cardiovascular system will not result in an increase in blood
pressure or heart rate but may exhibit a cardioprotective
eﬀect. This cardiovascular receptor response may explain
why an increase in heart rate or blood pressure is generally
not seen when p-synephrine is used alone or when caﬀeine
is combined with p-synephrine or bitter orange extract in
dietary supplements, in spite of the fact that caﬀeine alone
is well known to aﬀect these parameters [53], particularly in
caﬀeine-sensitive individuals [54].
It is worth noting that octopamine receptors are present
in insects, mollusks, and other invertebrates and are believed
to represent counterparts of adrenoreceptors in vertebrates
[55,56].Octopaminefunctionsasaneuromodulator,neuro-
transmitter, and neurohormone in the nervous systems of
invertebrates [56]. Both α-a n dβ-adrenoreceptor-like octo-
pamine receptor subtypes have been observed and studied
[55, 57–59]. However, octopamine receptors diﬀer markedlyOxidative Medicine and Cellular Longevity 5
from mammalian adrenoreceptors in their ligand binding
characteristics.Forexample,p-synephrinehasbeenshownto
haveabindingaﬃnitysimilartooctopamineforoctopamine
receptors [60–62], while epinephrine, norepinephrine, tyr-
amine, phenylethylamine, phenylethanolamine, and dop-
amine either have no eﬀect or moderate eﬀect [61, 62].
Thus, the relative binding aﬃnities for octopamine receptors
are vastly diﬀerent from the binding aﬃnities and eﬀects
produced by these same ligands with respect to mammalian
adrenoreceptors, and as a consequence, one cannot mean-
ingfully extrapolate results from one system to the other.
In summary, the binding studies discussed above pro-
vide extensive evidence that the meta-a n dparaisomers of
synephrine do not exhibit similar receptor binding and
provide a mechanistic understanding for the vastly diﬀerent
pharmacological eﬀects of the two isomers. The assumption
that the two forms of synephrine have similar if not identical
eﬀects has lead to misinformation and the inappropriate
attribution of potentially adverse eﬀects produced by m-
synephrine to p-synephrine, with only the latter occurring
naturally in plant materials included in bitter orange [26].
Furthermore, structural diﬀerences and the resultant altered
receptor-binding aﬃnities also explain the markedly diﬀer-
ing pharmacological responses to similar concentrations and
doses of p-synephrine relative to ephedrine, norepinephrine,
and other biogenic amines.
3.ObservedCardiovascularEffects
The receptor binding studies discussed above provide a
mechanistic understanding for the observed eﬀects of p-
synephrine in human clinical studies as well as in animals.
The vast majority of human clinical studies have noted
that p-synephrine and bitter orange extract either alone or
in combination with caﬀeine and other ingredients have
no eﬀect on blood pressure [19, 20, 63–71]o rh e a r tr a t e
[19, 33, 63–71], in spite of the widely postulated assumption
that these eﬀects would occur [19–23, 72–74]. Animal
studiesinvolvingorallyadministeredp-synephrineandbitter
orange extract have similarly demonstrated the absence of
cardiovascular aﬀects [34, 75–77], consistent with the poor
binding aﬃnity of p-synephrine for α-a sw e l la sβ-1 and β-
2 adrenoreceptors. Huang et al. [77] have shown that at a
dose of 1mg/kg orally twice a day in two models of portal
hypertensive rats, p-synephrine signiﬁcantly ameliorated the
hyperdynamic eﬀects.
Several human studies involving products that contained
p-synephrine in addition to other constituents including
caﬀeine have reported increases in blood pressure [71, 78]
and heart rate [33, 71], and the authors have suggested
that these eﬀects may be due to p-synephrine. The study by
Haller et al. [33] demonstrated that a single oral dose of p-
synephrine alone (46.9mg, as 6% p-synephrine in a bitter




a meal three hours after receiving the p-synephrine, and
the thermic and cardiovascular eﬀects of food have been
demonstrated in other studies [66]. In addition, the half-life
of p-synephrine is two to three hours [33, 71, 79], and as a
consequence, it is doubtful that one would expect to see a
signiﬁcant cardiovascular eﬀect after two to three half-lives
when none occurred at earlier time points.
Another study reported small, statistically signiﬁcant but
clinically insigniﬁcant increases in heart rate and blood
pressure[78]followingoraladministration ofabitterorange
extract preparation reported to contain 54mg p-synephrine.
However, a study by Min et al. [64] using the same product
in a similarly designed randomized, placebo-controlled
crossover study observed no eﬀect on systolic or diastolic
blood pressure or on the rate-corrected QT (QTc) interval.
One eight-week placebo-controlled double-blind study has
reported a small but signiﬁcant decrease in systolic and
diastolic blood pressures following ingestion of a product
containing a Citrus peel extract [80]. A signiﬁcant loss of
weight as well as decreases in fasting glucose, triglycerides,
and cholesterol were also observed.
McGuﬃn[ 16] reviewed the FDA adverse events reports
concerningbitterorangepriorto2004andconcludedthatno
adverse events could be attributed directly to bitter orange
extract or p-synephrine. Subsequently, Stohs [17]r e v i e w e d
and assessed the 22 FDA adverse event reports (AERs) from
April 2004 through October 2009 associated with bitter-
orange-containingproducts,aswellas10clinicalcasereports
published during this time interval which purported to link
bitter-orange-containing weight management products with
cardiovascular incidents and other adverse events. In each
case, the authors implicated bitter-orange extract and/or
p-synephrine as the possible causative agent. However, in
all AERs and case reports, the products involved were
polyherbal, polyalkaloidal and poly-protoalkaloidal, and as
a consequence, it is not possible or plausible to ascribe the
observed eﬀects to a single ingredient.
A wide range of confounding factors existed among the
published case reports including a history of obesity, heart
murmur, preexisting heart disease, hypertriglyceridemia,
sickle cell trait, dehydration, pneumonia, smoking, physical
inactivity, possible use of anabolic steroids and/or perfor-
mance enhancing drugs, gastroesophageal disease, high caf-
feineintake,andhighalcoholconsumption[17].Inaddition,
products were not always being taken as recommended, and
it was not always clear if the subjects were using other
unreported dietary supplements and/or drugs. The high
caﬀeine intake associated with the products in question may
have also been a contributing factor [17]. The observed
eﬀects may have been due to a combination of ingredients.
Finally, the possibility exists that the consumption of the
productand theadverse eventwereconcurrentbutunrelated
since millions of individuals use p-synephrine-containing
dietary supplements and food products on a daily basis while
millions of cardiovascular events occur annually.
In summary, the results of human clinical and animal
studies involving p-synephrine are consistent with the results
of adrenoreceptor binding studies. The observed lack of
cardiovascular eﬀects of orally administered p-synephrine is
in concert with its poor binding aﬃnity for α-a sw e l la sβ-1
and β-2 adrenoreceptors.6 Oxidative Medicine and Cellular Longevity
4. WeightLoss and WeightManagement Effects
If p-synephrine binds to and activates β-3 adrenorecep-
tors, an increase in thermogenesis and lipolysis should
be expected. Various animal studies have shown that the
oral administration of p-synephrine or p-synephrine in
the form of bitter orange extract results in weight loss or
decreased weight gain [46, 75, 76]. The thermic eﬀect of
orally administered p-synephrine (26mg) was demonstrated
in a ﬁve-hour human clinical study involving 30 subjects
[66]. Stohs et al. [69] have recently shown that the oral
administration of 50mg p-synephrine (30% p-synephrine as
Advantra Z) increased resting metabolic rate with no eﬀect
on heart rate or blood pressure in humans in a double-
blinded, randomized placebo-controlled study.
p-synephrine in the form of bitter orange extract is
widely used in conjunction with other ingredients in prod-
ucts designed to support weight loss/weight management
and/or enhance sports performance. Both published and
unpublished clinical studies have been extensively reviewed
byStohsandShara[81,82],andvariousstudieshavedemon-
strated modest weight loss. However, since p-synephrine is
combined with other ingredients as caﬀeine and various
herbal constituents, it is not possible to directly attribute the
thermogenic and weight loss eﬀects of the products to p-
synephrine. Unfortunately, the eﬀect of p-synephrine alone
on weight loss in a long-term human study has not been
assessed.
The eﬀect of a performance-enhancing dietary supple-
ment containing p-synephrine was examined under resting
and exercise conditions [71]. Exercise was perceived as being
less strenuous after consumption of the product. However,
the product contained p-synephrine as well as other herbal
ingredients, and as a consequence, the eﬀects cannot be
speciﬁcally ascribed to p-synephrine.
5. Summary and Conclusions
Receptor binding studies involving tissues from humans and
animals indicate that p-synephrine exhibits poor binding
aﬃnities for α-adrenoreceptor subtypes as well as β-1 and β-
2 adrenoreceptors relative to norepinephrine, m-synephrine,
ephedrine, and other amines. Activation of these receptors
is associated with increased vasoconstriction, cardiovascu-
lar constriction, and heart rate. Studies in animals and
humans have demonstrated that p-synephrine exhibits little
or no cardiovascular activity when administered orally either
alone or in the form of products containing multiple
ingredients.
A number of case reports have implied that p-synephrine
and/or bitter orange extract may have been responsible for
adverse cardiovascular and other events. However, in each
case, the product presumably consumed was polyherbal as
well as polyalkaloidal and poly-protoalkaloidal, and as such,
the adverse eﬀect involved cannot be directly ascribed to p-
synephrine. Furthermore, various confounding factors were
involved,andanumberofplausibleexplanationsexistforthe
observed eﬀects. Several recent investigations involving the
administration of p-synephrine to human subjects at doses
higher than those present in the clinical case reports have not
observed cardiovascular eﬀects.
Several studies indicate that p-synephrine may bind to
β-3 adrenoreceptors which is associated with thermogenesis,
lipolysis, glucose as well as cholesterol metabolism, and pos-
sibly reduced food intake. More deﬁnitive studies involving
p-synephrine and β-3 adrenoreceptors are needed. Unfor-
tunately, an appropriate ligand for the β-3 adrenoreceptor
currently does not exist. However, measuring a functional
response such as cyclic AMP elevation in a human adipocyte
cell line that expresses the β-3 adrenoreceptor, and assessing
potencies of antagonists to block this response may be
appropriate. Several animal studies have clearly shown that
oral p-synephrine administration can support weight loss
and/or reduced weight gain without adverse cardiovascular
eﬀects. A number of human clinical studies involving oral
administration of multi-ingredient products containing p-
synephrine have demonstrated modest weight loss, although
weight loss has not occurred in all cases. No human study
involving the long-term administration of p-synephrine
alone has been conducted with respect to weight loss and
weight management, and the need for this study is apparent.
p-synephrine has been shown to bind to octopamine
receptor subtypes in invertebrates. These receptors are
believed to be analogous to adrenoreceptors in vertebrates.
However, the binding aﬃnities of various amines includ-
ing p-synephrine, m-synephrine, and norepinephrine to
octopamine receptors are markedly diﬀerent and clearly
unrelated to their binding characteristics to adrenoreceptors.
As a consequence, the binding of p-synephrine to octop-
amine receptors cannot be extrapolated to adrenoreceptors
in humans and other vertebrates.
In general, additional human studies are required involv-
ing long-term safety and weight loss where p-synephrine is
administered alone and/or with a small number of selected
and clearly deﬁned additional ingredients as opposed to
being included in complex multiherbal products. Further-
more, additional p-synephrine adrenoreceptor binding stud-
ies are needed, in particular, involving β-3 adrenoreceptors
in order to provide greater clarity with respect to both safety
and eﬃcacy.
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